Per agreement with Galderma, Anika reaquires rights to Elevess dermal filler products

January 3, 2008

Bedford, Mass. - Anika Therapeutics, based here, announced that Anika and Galderma have finalized their agreement to terminate all license, development and supply arrangements involving the Elevess family of filler products, reports MedicalNewsToday.com.

Bedford, Mass. - Anika Therapeutics, based here, announced that Anika and Galderma have finalized their agreement to terminate all license, development and supply arrangements involving the Elevess family of filler products, reports MedicalNewsToday.com.

The result is that Anika has now reacquired the worldwide rights to the future development and marketing of Elevess, including ownership of the trademark and all related packaging, marketing and promotional materials, as well all clinical studies, marketing research and training materials developed by Galderma.

MedicalNewsToday quotes Anika Vice President Gregory T. Fulton as saying, “We have begun moving forward in the search for a new partner for Elevess. There has been considerable interest expressed already by new potential partners, and we are actively pursuing these opportunities. In addition, we are continuing with pre-launch activities, which include reaching out to key opinion leaders. We plan to launch Elevess in the first half of (2008) and are confident that we will execute on our strategy to make dermal fillers an important franchise for the company.”

According to Anika, hyaluronic acid-based Elevess is the first injectable soft-tissue filler for facial wrinkles, scar remediation and lip augmentation to incorporate lidocaine. Elevess has been approved for sale in the United States, the European Union and Canada.